Know Diabetes by Heart A Partnership to Improve Cardiovascular Outcomes in Type 2 Diabetes Mellitus

被引：6
|
作者：
Sanchez, Eduardo J. [1 ]
Cefalu, William T. [2 ]
机构：
[1] Amer Heart Assoc, 7272 Greenville Ave, Dallas, TX 75231 USA
[2] Amer Diabet Assoc, Arlington, VA USA
来源：
CIRCULATION | 2019年 / 140卷 / 07期
关键词：
cardiovascular risk factors; diabetes mellitus;
D O I：
10.1161/CIRCULATIONAHA.119.039161
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：526 / 528
页数：3
相关论文
共 50 条
  • [1] Cardiovascular Outcomes Trials in Type 2 Diabetes Mellitus
    Kapoor, Karan
    George, Praveen
    Miller, Michael
    [J]. CARDIOLOGY, 2016, 135 (02) : 108 - 126
  • [2] Intensive glycaemic control in type 2 diabetes mellitus: Does it improve cardiovascular outcomes?
    Reddy, Sagili Vijaya Bhaskar
    Bhatia, Eesh
    [J]. NATIONAL MEDICAL JOURNAL OF INDIA, 2011, 24 (01): : 21 - 27
  • [3] Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    Scirica, Benjamin M.
    Bhatt, Deepak L.
    Braunwald, Eugene
    Steg, P. Gabriel
    Davidson, Jaime
    Hirshberg, Boaz
    Ohman, Peter
    Frederich, Robert
    Wiviott, Stephen D.
    Hoffman, Elaine B.
    Cavender, Matthew A.
    Udell, Jacob A.
    Desai, Nihar R.
    Mosenzon, Ofri
    McGuire, Darren K.
    Ray, Kausik K.
    Leiter, Lawrence A.
    Raz, Itamar
    Braunwald, Eugene
    Bhatt, Deepak L.
    Scirica, Benjamin M.
    Udell, Jacob A.
    Cavender, Matthew A.
    Desai, Nihar
    Abrahamsen, Timothy
    Grossman, Michelle
    Morin, Suzanne
    Im, Kyungah
    Hoffman, Elaine
    Gabovitch, Daniel
    Pricken, Alexandra
    Mosenzon, Ofri
    Buskila, Alona
    Ohman, Peter
    Hirshberg, Boaz
    Stahre, Christina
    Price, Deborah
    Billing-Clason, Solveig
    Sabel, Karin
    Monyak, John
    Sjostrand, Mikalea
    Wei, Cheryl
    Lu, Jane
    Miller, Elinor
    Raichlen, Joel
    Fitt, Sandy
    Frederich, Robert
    Iqbal, Nayyar
    Donovan, Mark
    Davidson, Jaime A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (14): : 1317 - 1326
  • [4] Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus
    Jaeschke, Roman
    Gerstein, Hertzel
    [J]. POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ-POLISH ARCHIVES OF INTERNAL MEDICINE, 2016, 126 (10): : 803 - 805
  • [5] Exploring heart failure events in contemporary cardiovascular outcomes trials in type 2 diabetes mellitus
    Vijayakumar, Shilpa
    Vaduganathan, Muthiah
    Butler, Javed
    [J]. EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2018, 16 (02) : 123 - 131
  • [6] Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon
    Buse, JB
    Rosenstock, J
    [J]. CARDIOLOGY CLINICS, 2005, 23 (02) : 211 - +
  • [7] Prevention of cardiovascular outcomes in type 2 diabetes mellitus: Trials on the horizon
    Buse, JB
    Rosenstock, J
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2005, 34 (01) : 221 - +
  • [8] Risk Factors and cardiovascular Outcomes in Patients with type 2 Diabetes Mellitus
    Pavlicek, Vojtech
    [J]. DIABETOLOGE, 2018, 14 (07): : 499 - 500
  • [9] Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes
    Chi, Cecilia
    Snaith, Jennifer
    Gunton, Jenny E.
    [J]. HEART LUNG AND CIRCULATION, 2017, 26 (11): : 1133 - 1141
  • [10] Empagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk
    Inzucchi, Silvio E.
    Wanner, Christoph
    Lachin, John M.
    Fitchett, David
    Bluhmki, Erich
    Hantel, Stefan
    Mattheus, Michaela
    Devins, Theresa
    Johansen, Odd Erik
    Woerle, Hans Juergen
    Broedl, Uli C.
    Zinman, Bernard
    [J]. CIRCULATION, 2015, 132 (23) : 2271 - 2271
12345